Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Editas Medicine, Inc.
Type
Public
Traded as NASDAQ: EDIT
Industry Pharmaceutical company
Headquarters Cambridge, Massachusetts
Website www.editasmedicine.com

Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use "DNA itself to internally treat afflictions". The company has conceded that “It will be many years, if ever, before we have a product candidate ready for commercialization.” Further, the company's valuation depends on a single patent, which holder was in dispute as of early 2016, presenting a major risk to the company's continued viability.

The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Juno's experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics.

The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Leber's congenital amaurosis, a rare genetic illness that causes blindness.

Direct competitors to Editas include Crispr Therapeutics, Intellia Therapeutics, and Caribou Biosciences.

Investment goal date:
Dividends reinvested
Editas Medicine, Inc. EDIT report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
713006
BlackRock Inc.
1118488
BlackRock Institutional Trust Company, N.A.
260639
Capital World Investors
1770000
CLOUGH CAPITAL PARTNERS L P
392087
CREDIT SUISSE AG/
154013
D. E. Shaw & Co., Inc.
244929
DEERFIELD MANAGEMENT CO
1709400
FMR LLC
5901489
HIGHLAND CAPITAL MANAGEMENT LP
189000
LMR Partners LLP
153190
MORGAN STANLEY
308909
PRICE T ROWE ASSOCIATES INC /MD/
1401696
Vanguard Group, Inc
1935173
VIKING GLOBAL INVESTORS LP
1709401
Major Shareholders
Name Relationship
Total Shares
Holding stocks